Immutep Limited (ASX: IMM)
Immutep Limited (ASX: IMM), recently reported that it had entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.), through a subsidiary, to evaluate eftilagimod alfa (efti) in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in a pivotal Phase III trial.
Additionally, the company reported encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress.
In May 2024, the company also reported encouraging data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy, a standard-of-care treatment, plus KEYTRUDA for patients with soft tissue sarcoma (STS).
Immutep’s collaboration with MSD is poised to bolster the company's commercial efforts while potentially accelerating the development and advancement of its promising oncology pipeline.
Immutep with potential to become one of the Best Long Term Healthcare Stocks presents a highly compelling investment proposition underpinned by the potential to establish a dominant position in a vast oncology market. With an extraordinary cash and liquid position post-funding, Immutep Limited boasts a strong capital foundation to drive significant advancements and progress in its clinical pipeline over the coming years.
Optiscan Imaging Limited (ASX: OIL)
Optiscan Imaging Limited (ASX: OIL) recently announced the unveiling of its revolutionary new microscopic medical imaging device, InVue. Created to facilitate precision surgery, InVue offers real-time digital pathology access directly to surgeons. The device was developed and manufactured in Melbourne by Optiscan in collaboration with Design + Industry, an industrial design firm based in Sydney and Melbourne.
Earlier, on 13 May 2024, the company disclosed its collaboration with Mayo Clinic through a know-how agreement to develop a digital confocal laser endomicroscopic imaging system for integration into robotic surgery.
Furthermore, the company in its quarterly results for the period ended 31 March 2024 announced that Optiscan had received a $3 million CRC-P grant from the Australian Government to develop its Edge-AI-enabled gastrointestinal flexible endomicroscope. Additionally, the company received a $672k R&D tax incentive rebate, enabling further investment in its successful multi-product portfolio development.
Moreover, Optiscan reported the establishment of a US Regional Office in Rochester, Minnesota, aimed at positioning the company at the heart of the US medtech hub.
Optiscan has pioneered a cutting-edge and potentially disruptive technology in real-time, non-invasive microscopic imaging. This innovation consistently delivers significant improvements in patient and medical outcomes, particularly in cancer screening and surgical margin assessment.
With a proven and patented technology foundation, the company is poised for market-leading commercialization prospects, presenting a potentially multi-bagger investment proposition over an extended timeframe. The total addressable market in breast cancer surgery alone, estimated at US$2.6 billion, underscores the substantial commercialization opportunity for Optiscan in the coming years.
Telix Pharmaceuticals Limited (ASX: TLX)
Telix Pharmaceuticals Limited (ASX: TLX) in its recently declared Q1 FY2024 results reported the surge in revenue to $175.0 million, marking an impressive 75% increase compared to Q1 2023.
Gross profit reached $115.4 million, demonstrating a remarkable 84% surge compared to the same quarter in the previous year. Its operating profit also improved significantly to $28.5 million in vast comparison from the $5.6 million operating loss reported in the prior corresponding quarter.
Telix as one of the Top ASX Healthcare Stocks has achieved remarkable revenue growth in recent years. Notably, revenues surged from $160 million in FY22 to $502 million in FY23, underscoring the company's robust growth trajectory, with the clinical pipeline providing a clear pathway for further expansion.
Telix is strategically focused on achieving key regulatory milestones in the short term. Its expansive global operational footprint positions it to capitalize on significant market opportunities, bolstered by a robust pipeline of clinical prospects.
Source - Company Reports
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.